Searching…
Dec 23, 2025 · Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) is an antibody-drug conjugate used to treat breast cancer.
KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin ®) and a taxane.
May 23, 2019 · Ado-trastuzumab emtansine (Kadcyla), or T-DM1, has been approved by FDA for use as adjuvant therapy in some women with early-stage HER2-positive breast cancer.
Dec 5, 2018 · Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients...
^ "New data from Phase III EMILIA study showed Roche's trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer" (Press release).
Sep 26, 2024 · T-DM1 chemotherapy refers to treatment with Kadcyla, which is a targeted treatment that may be used to treat HER2-positive breast cancer in women who meet certain criteria.
T-DM1 is used in locally advanced or metastatic HER2-positive breast cancer after prior treatment with trastuzumab and taxane, based on the EMILIA trial, and was approved by the Food and Drug Administration (FDA) for ...
Learn how certain types of breast cancer can be treated with trastuzumab emtansine (Kadcyla, TDM1). Find out who it’s for and the possible side effects.
Jul 23, 2025 · T-DM1, also known by its brand name Kadcyla, represents a significant advancement in the field of cancer treatment. It is a specific type of medication classified as an antibody-drug conjugate (ADC), de...
May 28, 2025 · Our study supports the use of TDM1 as a viable option for treating HER2-positive MBC in routine clinical practice, confirming its effectiveness and safety profile observed in clinical trials.
